Troubled EpiCept's shareholders clamor for Immune Pharma merger
This article was originally published in Scrip
Executive Summary
EpiCept's shareholders have shouted their approval of the failing company's merger with Israeli company Immune Pharmaceuticals, with 92% of the votes cast at the company's 6 August meeting in favor of the deal.